Drugs / P2-VP8 subunit rotavirus vaccine
P2-VP8 subunit rotavirus vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01764256 | Dec 2012 → Jun 2013 | Rotavirus infection | PATH | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | P2-VP8 subunit rotavirus vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01764256 ↗ |
| Known as | P2-VP8 | “METHODS: Three groups of 16 adults were randomized to receive three injections of P2-VP8 (12) or placebo (4) at doses of 10, 30 or 60 μg of vaccine.” PMID 26065919 ↗ Jun 2015 |
| Known as | P2-VP8 subunit vaccine | “The P2-VP8 subunit vaccine for the prevention of rotavirus gastroenteritis is comprised of a truncated VP8 subunit protein from the rotavirus Wa strain (G1[P8]) fused to the...” PMID 26065919 ↗ Jun 2015 |
| Modality | Vaccine | “The P2-VP8 subunit vaccine for the prevention of rotavirus gastroenteritis” PMID 26065919 ↗ Jun 2015 |
| Route | Intramuscular | “adsorbed on aluminum hydroxide for intramuscular administration.” PMID 26065919 ↗ Jun 2015 |